Change over period: —
NSE · AUROPHARMA
AUROB.PHARMA
-3.2% from the 52-week high · +60.1% above the low
Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 15,690 full-time employees. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.
The short version. AUROB.PHARMA reported revenue of ₹10,263 crore for Sep 2026, up 23.9% from a year earlier. Net profit was ₹1,126 crore (up 32.8% year on year). Return on equity was 9.2% in Mar 2026. Promoter holding was 51.87% in Sep 2026, up 0.05 points over 8 quarters.
1 · The price
How has the stock traded?
AUROB.PHARMA trades 3.2% below its 52-week high and 60.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹10,263 cr.
Sep 2026 net profit of ₹1,126 cr.
0.8 pts higher than a year earlier.
Revenue compounded at 10.7% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10263 | 9150 | 8853 | 8646 | 8286 | 7868 | 8382 | 7979 |
| Net profit | 1126 | 1033 | 921 | 910 | 848 | 825 | 903 | 846 |
| Net margin % | 11.0 | 11.3 | 10.4 | 10.5 | 10.2 | 10.5 | 10.8 | 10.6 |
| EPS (₹) | 19.57 | 17.95 | 15.86 | 15.67 | 14.61 | 14.2 | 15.56 | 14.56 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 33653 | 31724 | 29002 | 24855 | 23455 | 24775 | 23098 | 19564 |
| Net profit | 3505 | 3486 | 3173 | 1928 | 2648 | 5335 | 2831 | 2365 |
| Net margin % | 10.4 | 11.0 | 10.9 | 7.8 | 11.3 | 21.5 | 12.3 | 12.1 |
| EPS (₹) | 60.34 | 60.02 | 54.15 | 32.9 | 45.2 | 91.05 | 48.32 | 40.36 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 9.2% in Mar 2026; debt to equity is 0.20.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 9.2 | 10.7 | 10.6 | 7.2 |
| Return on capital % | 13.6 | 15.8 | 14.3 | 9.7 |
| EBITDA margin % | 21.3 | 22.3 | 21.0 | 15.9 |
| Net margin % | 10.3 | 10.8 | 10.7 | 7.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 10.7% | 6.3% |
| Profit CAGR | 22.1% | -8.1% |
4 · The owners
Who holds it, and are they adding?
Up 0.05 pts over 8 quarters.
Up 1.12 pts over 8 quarters.
Down 0.78 pts over 8 quarters.
+53 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 | 51.82 | 51.88 | 51.87 | +0.05 |
| FII | 16.29 | 15.33 | 14.37 | 14.21 | 13.94 | 15.24 | 16.38 | 17.41 | +1.12 |
| DII | 25.2 | 26.23 | 26.93 | 27.6 | 27.68 | 25.87 | 25.1 | 24.42 | -0.78 |
| Public | 6.69 | 6.61 | 6.87 | 6.38 | 6.55 | 7.08 | 6.64 | 6.29 | -0.4 |
Mutual fund holdings · Oct 2026
279 schemes hold this stock
226 the month before.
- quant Manufacturing Fund10.2% of NAV
- quant Mid Cap Fund10.14% of NAV
- quant Dynamic Asset Allocation Fund10.06% of NAV
- quant Multi Cap Fund9.94% of NAV
- quant Momentum Fund9.92% of NAV
- quant Large & Mid Cap Fund9.86% of NAV
- quant Healthcare Fund9.83% of NAV
- quant Business Cycle Fund9.7% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for AUROB.PHARMA are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about AUROB.PHARMA
What is the AUROB.PHARMA share price?
AUROB.PHARMA (AUROPHARMA) last closed at ₹1,805.70, up 0.52% on the day. Its 52-week range is ₹1,121.70 to ₹1,855.30.
What is the market cap of AUROB.PHARMA?
AUROB.PHARMA has a market capitalisation of about ₹103,625 crore. Its price-to-earnings ratio is 27.3.
How are AUROB.PHARMA's latest results?
AUROB.PHARMA reported revenue of ₹10,263 crore for Sep 2026, up 23.9% from a year earlier. Net profit was ₹1,126 crore (up 32.8% year on year). Return on equity was 9.2% in Mar 2026. Promoter holding was 51.87% in Sep 2026, up 0.05 points over 8 quarters.
Who owns AUROB.PHARMA?
As of Sep 2026, shareholding was: Promoter 51.87%, FII 17.41%, DII 24.42%, Public 6.29%.
How many mutual funds hold AUROB.PHARMA?
279 mutual fund schemes held AUROB.PHARMA in October 2026. That compares with 226 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 08 Aug 2025 · Interim Dividend - Rs. 4
- 20 Feb 2024 · Interim Dividend - Rs. 1.5
- 20 Nov 2023 · Interim Dividend - Rs. 3
- 17 Feb 2023 · Interim Dividend - Rs. 3
- 06 Jun 2022 · Interim Dividend - Rs. 4.5
- 18 Feb 2022 · Interim Dividend - Rs. 1.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.